### Infection Prevention in Practice 5 (2023) 100273



Available online at www.sciencedirect.com

## Infection Prevention in Practice



journal homepage: www.elsevier.com/locate/ipip

# Sustained low catheter related infection (CRI) incidence in an observational follow-up study of 9924 catheters using automated data scripts as quality assurance for central venous catheter (CVC) management

## Mika M. Rockholt<sup>a, b, \*</sup>, Tobis Agrell<sup>c</sup>, Hulda Thorarinsdottir<sup>d</sup>, Thomas Kander<sup>a, c</sup>

<sup>a</sup> Department of Intensive and Perioperative Care, Skåne University Hospital, Lund, Sweden

<sup>b</sup> Department of Anesthesiology, Perioperative Care and Pain Medicine, NYU Langone Health, NYC, NY, USA

<sup>c</sup> Department of Clinical Sciences, Lund University, Sweden

<sup>d</sup> Department of Intensive and Perioperative Care, Landspitali University Hospital, Reykjavik, Iceland

## ARTICLE INFO

Article history: Received 25 May 2022 Accepted 8 February 2023 Available online 19 February 2023

Key words: Catheter-related infections Central venous catheter management Healthcare quality assurance Follow-up study Automatic data extraction Simple queries



## SUMMARY

**Background:** To maintain a low incidence of Catheter Related Infections (CRI) and Catheter Related Bloodstream Infections (CRBSI), continuous follow-up studies on catheter management are necessary. The aims of the present study were to investigate the incidence of catheter tip colonisation, CRI and CRBSI in the Region, to further explore the feasibility of automatic data collection and to investigate associations between independent variables and CRI.

*Methods:* Data from electronic patient charts on all documented central venous catheter (CVC) insertions from multiple hospitals in southern Sweden, between March 2019 and August 2020, were automatically extracted. Multivariable regression analyses were used to identify associated risk factors.

**Results:** In total, 9924 CVC insertions were included. The prevalence of CRI and CRBSI were 0.7% (n = 74) and 0.02% (n = 20) with incidences of 1.2/1000 catheter days and 0.3/ 1000 catheter days, respectively.

**Conclusions:** We found a sustained low incidence of CRI and CRBSI in the Region. Catheter tips were less likely to be colonised when the subclavian route was used compared to the internal jugular route and male sex as well as increased number of catheter lumens were associated with both catheter tip colonisation and CRI. By using automated scripts, data extraction was efficient and feasible but also demonstrated that real-time quality assurance should be recommended, since this is superior to current standard.

© 2023 The Authors. Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

https://doi.org/10.1016/j.infpip.2023.100273

<sup>\*</sup> Corresponding author. Address: Department of Intensive and Perioperative Care, Skåne University Hospital, Lund, 221 85, Sweden. *E-mail address:* mika.rockholt@med.lu.se (M.M. Rockholt).

<sup>2590-0889/© 2023</sup> The Authors. Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

## Introduction

Over the last decades, improvements in the management of central venous catheters (CVCs) have been made to reduce catheter related infections (CRIs), including catheter related bloodstream infections (CRBSIs). However, CRI continues to be a problem, causing not only increased patient suffering but also a burden on healthcare economy with reports showing that one CRI can cost up to \$32000 [1].

The view on CVC management and CRI prevention shifted in 2006 when Pronovost *et al.* described simple evidence-based interventions resulting in significant CRI reduction [2,3]. These interventions, also known as "insertion bundles" or "hygiene bundles", were implemented worldwide resulting in multiple reports on lowered CRI incidences [3]. In line with Pronovost's study, we introduced a simple hygiene insertion bundle in 2012 which was demonstrated effective as it reduced the incidence of CRI [4].

In contrast to the numerous publications reporting shortterm low incidences of CRI after the introduction of various hygiene bundles [2,4,5], there are relatively few follow-up studies evaluating CRI incidences over time and focusing on the long-term effects of hygiene bundles. In the past decade, one quality improvement report published in 2011 by Batistella *et al.* [6] and one follow-up study from 2014 by Hammarskjöld *et al.* [7] both describe a sustained low catheter infection rate, six years after implementing new catheter insertion routines. In summary, these studies confirmed safe and effective implementation of new CVC-management strategies. However, more recent reports on CRI incidences with follow-up studies worldwide are scarce.

In parallel, modernisation of health records and patient data over the last decades has led to the development of electronic health record (EHR) systems comprised by valuable data used in epidemiological studies, such as the ones reporting catheter-related and other life-threatening infections [8,9]. Several recent studies have reported electronic surveillance systems and the use of data engines and search queries to monitor and report the management of CVCs, allowing tracking of compliance to CVC hygiene insertion bundles but also to monitor the infection and complication frequencies [8,10,11].

In an attempt to evaluate long-term effects of the hygiene insertion bundle introduced in 2012 at the current institution, we used automated script-based search in the EHR to conduct this multicenter observational follow-up study as a quality assurance measure of CRI over time. The primary aim of this study was to investigate the incidence of CRI and CRBSI using an automated script-based method in an unselected, large, cohort of patients with central venous access [4]. Secondarily, we aimed to identify associated risk factors for CRI.

## Methods

This study was approved by the Swedish Ethical Review Authority (dnr 2014/916 and 2018/866) and requirement for written informed consent was waived. The study was carried out at the Department of Intensive and Perioperative Care at Skåne University Hospital, Lund, Sweden. The manuscript was prepared according to the STROBE guidelines for observational studies. All documented CVC insertions from ten different hospitals within the Scania Region (Region Skåne), Sweden, from March 2019 to August 2020 were eligible for inclusion. Exclusion criteria included patients under 8 years of age, missing insertion date or unknown insertion site. Peripherally inserted catheters (PICC-lines) and subcutaneous venous ports were not included as they were inserted using different techniques and different hygiene precautions.

## CVC insertion, management, and removal

CVC insertions were performed according to Regional guidelines, previously described<sup>(4, 12)</sup>. Some of the variables included in the template are described in Table I.

Catheter tips were only cultured if a CRI was suspected. CVCs were removed after site treatment with 0.5% chlorhexidine in 70% alcohol. The distal end of the CVC was submerged into a culture tube, and the distal 5cm was cut off. The tip was cultured using a semi-quantitative method where growth of >102 CFU/catheter tip was considered significant colonization [13,14]. Blood cultures taken between 0 - 48h after CVC removal were included in the data set. The automated BACT/ ALERT®-system (BioMérieux, Marcy l'Etoile, France) was used and all cultures were incubated until microbial growth was detected or for a maximum of five days.

## Data extraction

By using an automated script-base search in the EHR (Melior, Cerner, North Kansas City (MO), USA), all documented CVCinsertion templated, during the study period, were extracted. Automatically extracted data was directly inserted into a compiled, encrypted database (Excel, version 10, Microsoft, Santa Rosa, USA), where each individual insertion was merged with matching microbiological data, laboratory values obtained within 48 hours prior to the CVC removal. All insertions with data fulfilling the exclusion criteria were removed from the database.

## Outcomes and definitions

The primary outcomes were defined according to the definitions used by Centers for Disease Control and Prevention (CDC) [15]. Catheter tip colonisation was defined as a positive tip culture in a patient where suspected catheter infection had led to removal of the CVC, regardless of clinical symptoms. CRI was defined as positive tip culture combined with two or more systemic inflammatory response syndrome (SIRS) criteria (fever >38 or <36 C°, respiratory rate >20 breaths per minute, heart rate >90 beats per minute or white blood cell count >12000/µL or <4000/µL) upon CVC removal and no likely explanation other than the catheter. The diagnosis of CRBSI required fulfillment of the CRI-criteria combined with a peripheral blood culture taken within 48h prior to CVC removal, with the same microorganism isolated in both cultures.

## Statistics and analyses

All analyses were performed using SPSS (version 28, IBM, New York, USA) using data from the original dataset. Results were expressed as a median [interquartile range] for continuous variables and a number (percentage) for categorical

Table I

Baseline variables for patients receiving a central venous catheter (CVC)<sup>a</sup>

	Jugular vein n=8398	Subclavian vein n=1330	Femoral vein n=196	All n=9924
Number of patients	5989	1176	169	6872
Age, years	70 [58–77]	67 [53–75]	60 [46-73]	69 [57–76]
Sex, male	5099 (61)	828 (62)	111 (57)	6038 (61)
Indication for CVC <sup>b</sup>				× ,
Vessel irritating medication	2797 (33)	583 (44)	72 (37)	3452 (35)
Cardiac surgery	2820 (34)	277 (21)	9 (5.0)	3106 (31)
Parenteral nutrition	1251 (15)	196 (15)	9 (5.0)	1456 (15)
Haemodynamic monitoring	2007 (24)	259 (19)	30 (15)	2296 (23)
Peripheral venous access impossible	1640 (20)	339 (25)	34 (17)	2013 (20)
Blood sampling	2436 (29)	461 (35)	45 (23)	2942 (30)
Fluid resuscitation	1496 (18)	143 (11)	43 (22)	1682 (17)
Others	1176 (14)	101 (8.0)	86 (44)	1363 (14)
Missing	174 (2.0)	58 (4.0)	6 (3.0)	238 (2.0)
Type of catheter				
Central Venous Catheter (CVC)	8036 (96)	1312 (99)	142 (72)	9490 (96)
Central Haemodialysis Catheter (CHC)	362 (4.0)	18 (1.0)	54 (28)	434 (4.0)
Number of CVC lumen				
1	2275 (27)	353 (27)	19 (9.0)	2647 (27)
2	1859 (22)	311 (23)	19 (9.0)	2189 (22)
3	2374 (28)	380 (29)	41 (22)	2795 (28)
4	587 (7.0)	74 (5.0)	5 (3.0)	666 (7.0)
5	799 (10)	158 (12)	46 (23)	1003 (10)
Missing	504 (6.0)	54 (4.0)	66 (34)	624 (6.0)
Anticoagulant treatment before insertion		050 (70)		
No	5441 (65)	952 (72)	128 (65)	6521 (66)
Wartarin New vite wie K Anterewiet Orel Antiere wile ste	3/4 (4.0)	43 (3.0)	2 (1.0)	419 (4.0)
Non-vitamin K Antagonist Oral Anticoagulants	427 (5.0)	45 (3.0) 122 (10)	6 (3.U) 14 (7.0)	4/8 (5.0)
Acetylsalicylic acid	700 (P 0)	132 (10)	14 (7.0)	
Other	709 (8.0)	09 (7.0) 102 (8.0)	10 (9.0) 25 (19)	010 (0.0)
Processulant treatment before incertion <sup>d</sup>	702 (9.0)	103 (0.0)	33 (10)	900 (9.0)
No	7282 (87)	1150 (87)	153 (78)	8594 (87)
Distolet transfusion	110 (1 0)	54 (4 0)	8 (10)	172 (2 0)
Activated prothrombin complex	217 (3.0)	18 (1 0)	9 (4.0) 9 (5 0)	$\frac{172}{244}$ (2.5)
Vitamin K	87 (1.0)	6 (0.5)	5 (3.0)	93 (1 0)
Fibringen	35 (0.4)	7 (0 5)	3 (2,0)	45 (0.5)
Plasma	49 (0.5)	7 (0.5)	3 (2.0)	59 (1.0)
Tranexamic acid	71 (0.8)	11 (1.0)	4 (2,0)	86 (1.0)
Desmopressin	15 (0.2)	3 (0.2)	1 (1.0)	19 (0.2)
Other	753 (9.0)	96 (7.0)	27 (14)	876 (9.0)
Room for CVC-insertion			( )	
Operating theatre	4942 (59)	395 (30)	33 (17)	5370 (54)
Intensive Care Unit	2022 (24)	469 (35)	125 (64)	2616 (26)
Room reserved for CVC-insertion	902 (11)	399 (30)	22 (11)	1323 (13)
General ward	242 (3.0)	40 (3.0)	6 (3.0)	288 (3.0)
Missing	290 (3.0)	27 (2.0)	10 (5.0)	327 (3.0)
Department of admission at CVC insertion				
Surgical ward	4504 (54)	513 (39)	28 (14)	5045 (51)
Medical ward	2282 (27)	569 (43)	59 (30)	2910 (29)
Intensive Care Unit	1335 (16)	198 (15)	91 (46)	1624 (16)
Missing	277 (3.0)	50 (4.0)	18 (9.0)	345 (4.0)
Number of skin punctures				
1	6302 (75)	1017 (76)	149 (76)	7468 (75)
2	1333 (16)	193 (15)	20 (11)	1546 (16)
3	437 (5.0)	67 (5.0)	12 (6.0)	516 (5.0)
4	100 (1.0)	21 (2.0)	1 (0.5)	122 (1.0)
5 or more	45 (0.5)	12 (1.0)	3 (1.0)	60 (0.5)
			(continued o	n next page)

#### Table I (continued)

	Jugular vein n=8398	Subclavian vein n=1330	Femoral vein n=196	All n=9924
Missing	181 (2.5)	20 (1.0)	11 (5.5)	212 (2.0)
Number of vessel punctures				
1	6584 (78)	1130 (85)	154 (79)	7868 (79)
2	1209 (14)	143 (11)	18 (8.5)	1370 (14)
3	334 (4.0)	22 (1.5)	5 (3.0)	361 (4.0)
4	51 (0.5)	7 (0.5)	1 (0.5)	59 (0.5)
5 or more	16 (0.5)	2 (0.5)	2 (1.0)	20 (0.5)
Missing	204 (3.0)	26 (1.5)	16 (8.0)	246 (2.0)
Immediate mechanical complications				
Any	453 (5.5)	66 (5.0)	27 (14)	546 (5.5)
Failed insertion <sup>e</sup>	177 (2.1)	27 (2.0)	12 (6.1)	216 (2.2)
Bleeding <sup>f</sup>	131 (1.6)	13 (1.0)	10 (5.1)	154 (1.6)
Punctured artery	87 (1.0)	16 (1.2)	5 (2.6)	108 (1.1)
Arrhythmia	47 (0.6)	6 (0.5)	0 (0.0)	53 (0.5)
Pneumothorax	11 (0.1)	4 (0.3)	0 (0.0)	15 (0.1)
Total catheter days	48899	12725	916	62540
Days with catheter	5 [2—9]	6 [3–14]	3 [1-7]	5 [2—10]
Missing	1779 (21)	260 (20)	31 (16)	2070 (21)

<sup>a</sup> Numbers are presented as number (%) and continuous variables are presented as median [interquartile range].

<sup>b</sup> Registering multiple indications for one insertion was possible. Example of indications labeled as "Other" were introducer, pacemaker, continuous renal replacement therapy or dialysis.

<sup>c</sup> Registering multiple anticoagulative treatments for one insertion was possible.

<sup>d</sup> Registering multiple thrombotic treatments for one insertion was possible.

<sup>e</sup> "Failed insertions" included insertions with change of blood vessel and insertion attempts where no CVC was inserted.

<sup>f</sup> Grade 1 bleedings were not registered in this study. In this study 99.4 % of all bleedings could be classified according to Common Terminology Criteria for Adverse Events (CTCAE; Version 5.0) as grade 2. One grade 4 bleeding occurred also included in the" Bleeding" category.

variables. Baseline variables were considered as potential independent variables and differences between cases with tip colonisation and CRI were tested against controls using univariate regression analyses. Given a presumed complex interdependence of the independent variables, we also performed a multivariable logistic regression for all outcomes. The number of independent variables in the multivariable logistic regression models was limited so that maximum one independent variables per ten events was included. The selection of independent variables in the multivariable regression model was based on results from previous studies and results from the univariate analyses [4,7,12,16]. The Hosmer-Lemeshow test was used to test goodness of fit for multivariable testing. P < 0.05 was considered significant and all tests were two tailed.

## Results

In summary, a total of 9924 catheter insertions in 6872 patients were included in the study during the study period of 18 months (Figure 1). Data from the CVC insertion template, automatically extracted from the EHR, are presented as baseline characteristics of patients and CVCs in Table I. The most common insertion site was the jugular vein (85%) and the majority of catheters were inserted in an operating theatre (54%). Immediate complications after CVC insertion occurred in 5.5% of cases, where failed insertion (change of

blood vessel or abandoned attempt of insertion) was most common (2.2%), followed by bleeding (1.6%) and punctured artery (1.1%).

In total, 2304 (23%) CVCs were sent for culture (Figure 1). A total of 257 (2.6%) of all 9924 catheters demonstrated a positive tip culture, yielding a colonisation incidence of 4.1 tip colonisations/1000 catheter days. Further, CRI was confirmed in 74 cases (0.7%) yielding a CRI incidence of 1.2/1000 catheter days. Simultaneous blood culture and tip cultures were obtained in 667 cases (6.7%) with suspected infection where these cultures yielded positive results in 69 cases (0.7%). However, only 20 cases met the criteria for CRBSI (0.2%), resulting in a CRBSI incidence of 0.3/1000 catheter days. Due to unknown catheter durations, a total of 2070 catheters (all without colonisation and positive tip culture) were excluded when calculating the incidences.

To evaluate any impact on the COVID-19 pandemic, a comparison between the prevalence of catheter colonisation/ CRI/CRBSI during six months in the pandemic and the corresponding six months the year before, was performed. The analyses demonstrated no differences between the periods (Table II).

All isolated organisms are presented in Table III. The pathogens isolated in tip and blood cultures predominantly consisted of *Staphylococci*, where *Staphylococcus epidermidis* was by far the most common species. In fact, S. *epidermidis* was the only coagulase negative staphylococcus identified in CRI and CRBSI. In tip cultures S. *epidermidis* was seen in 64%



**Figure 1.** Flow chart with the number of Catheter Tip Colonisations, Catheter Related Infections (CRI) and, Catheter Related Bloodstream Infection (CRBSI) between March 2019 and August 2020 in Region Skåne, Sweden. Abbreviations: SIRS, systemic inflammation response syndrome.<sup>a</sup> Peripherally inserted catheters, or insertion missing both insertion site and insertion date.

and S. *aureus* in 12% of all tip cultures. The microorganisms responsible for CRI and CRBSI respectively was S. *epidermidis* (66% and 40%), S. *aureus* (15% and 35%), various Gram negatives (12% and 10%) and yeasts (12% and 10%)

The univariate regression analysis is described in detail in Table IV. The goodness of fit in the multivariable regression

analyses showed a valid chi-square value (P> 0.05) for both models. The detailed results of the multivariable regression analyses are shown in Table V. In summary, 13 independent variables were selected for investigation of tip colonisation (n=257) and seven independent variables for CRI (n=74). Male gender and increased number of catheter lumens were

Table II	
Impact of COVID-19 pandemic on colonisation, 0	CRI and CRBSI

Period	Colonisation	CRI	CRBSI
	(n=257)	(n=74)	(n=20)
March 2019-August 2019	94	27	7
March 2020-August 2020	96	28	7
	P = 0.8538	<i>P</i> = 0.9652	<i>P</i> = 0.9283

The study was conducted between March 2019 and August 2020. During this time-period, the included hospitals received patients with COVID-19 between March 2020 and August 2020. Prevalences were compared between March 2019—August 2019 and March 2020 -August 2020. Using the Chi-square test, no significant difference in infection prevalence was seen between the COVID-19 free period and the first wave of the COVID-19 pandemic.

independently associated with both catheter tip colonisation and CRI. Increased number of days with catheter and CVCs inserted in patients admitted to a medical ward were associated with increased tip colonisation, while catheters inserted in the subclavian vein were associated with decreased catheter tip colonisation compared with insertions in the jugular vein. As the frequency of CRBSI (n=20) was low, no regression analyses were performed for CRBSI. The characteristics of cases with CRBSI are presented in Table VI.

## Discussion

This observational multicentre follow-up study on 9924 CVC insertions demonstrated low incidences of CRI and CRBSI. Several associations between independent variables and CRI were identified, where catheter tips were observed as less likely to be colonised when the subclavian route was used compared to the internal jugular route and where male sex as well as increased number of catheter lumens were both associated with catheter tip colonisation and CRI. Furthermore, the automatic script-based extraction from the EHR was feasible and may be the base for future continuous CRI surveillance.

We designed the present study in an attempt to a follow-up of the results previously published by us where 1722 central venous catheter insertions inserted between the years 2011 and 2012 at a University Hospital in the same Region as the present, was investigated [4]. The previous study demonstrated an incidence of CRI and CRBSI of 1.86 and 0.62, per 1000 catheter days after the implementation of simple hygiene insertion bundles. In the present study the same point estimates were 1.2 and 0.3/1000 catheter days. These results indicate that the low incidence of CRI and CRBSI remains. However, it should be noted that there was significant time between the study periods, the present study included significantly more cases (9924 vs. 1722), used an automated script-base data-extraction from the EHR (compared to manual review), also included cases from the whole Scania Region and not only from one hospital.

Furthermore, the present study indicates that pathogens previously associated with CRI and CRBSI (Table III), as presented by Thorarinsdottir *et al.* [4], still represent most cases

[ah	مار	ш	
i ac	ne		

Isolated microorganisms from central venous catheter (CVC) tips<sup>a</sup>

OrganismColonised tips $(n=24)$ CRI $(n=20)$ $(n=257)$ CRBSI $(n=20)$ $(n=257)$ Gram positives:216 (84)66 (89)16 (80) S (40)Staphylococcus164 (64)49 (66)8 (40) $(0.0)$ Coagulase negative $(total)^b$ 5epidermidis152 (59)49 (66)8 (40) $(0.0)$ S. epidermidis152 (59)49 (66)8 (40) $(0.0)$ 0 (0.0)0 (0.0)S. epidermidis5 (1.9)0 (0.0)0 (0.0)S. capitis5 (1.9)0 (0.0)0 (0.0)S. caprae2 (0.8)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Enterococcus1 (1.1)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)Gram negatives:22 (9.0)9 (12)2 (10)Pseudomonas aeruginosa5 (2.0)3 (4.0)1 (5.0)Klebsiella $meumoniae$ 4 (2.0)1 (1.0)0 (0.0)Serratia marcescens4 (2.0)1 (1.0)0 (0.0)Seratia marcescens4 (2.0)1 (1.0)0 (0.0)Seratia marcescens4 (2.0)1 (1.0)0 (0.0)<	-			
tips (n=257)(n=74) (n=257)(n=20) (n=257)Gram positives:216 (84)66 (89)16 (80)Staphylococcus164 (64)49 (66)8 (40)Coagulase negative (total)S. epidermidis152 (59)49 (66)8 (40)S. warneri1 (0.4)0 (0.0)0 (0.0)S. capitis5 (1.9)0 (0.0)0 (0.0)S. caprae2 (0.8)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)Revelomonas aeruginosa5 (2.0)3 (4.0)1 (5.0)Klebsiella""""<""""	Organism	Colonised	CRI	CRBSI
(n=257)Gram positives:216 (84)66 (89)16 (80)Staphylococcus164 (64)49 (66)8 (40)Coagulase negative (total)bS. epidermidis152 (59)49 (66)8 (40)S. warneri1 (0.4)0 (0.0)0 (0.0)S. capitis5 (1.9)0 (0.0)0 (0.0)S. capitas1 (0.4)0 (0.0)0 (0.0)S. capitas1 (0.4)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)genegenes2 (0.8)2 (3.0)0 (0.0)Serratia marcescens4 (2.0)1 (1.0)0 (0.0)Setherichia coli3 (1.0)1 (1.0)0 (0.0)Other4 (2.0)1 (1.0)0 (0.0)glabrata3 (1.0)2 (3.0)1 (5.0)glabrata3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0) </td <td></td> <td>tips</td> <td>(n=74)</td> <td>(n=20)</td>		tips	(n=74)	(n=20)
Gram positives:216 (84)66 (89)16 (80)Staphylococcus164 (64)49 (66)8 (40)Coagulase negative (total)b $5. epidermidis$ 152 (59)49 (66)8 (40)S. epidermidis152 (59)49 (66)8 (40)0 (0.0)S. capitis5 (1.9)0 (0.0)0 (0.0)S. caprae2 (0.8)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)Gram negatives:22 (9.0)9 (12)2 (10)Pseudomonas aeruginosa5 (2.0)3 (4.0)1 (5.0)Klebsiella $pneumoniae$ 4 (2.0)1 (1.0)0 (0.0)Serratia marcescens4 (2.0)1 (1.0)1 (5.0)Escherichia coli3 (1.0)1 (1.0)0 (0.0)Other4 (2.0)1 (1.0)0 (0.0)Gram negatives:19 (7.0)9 (12)2 (10)Candida $albicans$ 8 (3.0)6 (8.0)1 (5.0) </td <td></td> <td>(n=257)</td> <td></td> <td></td>		(n=257)		
Staphylococcus164 (64)49 (66)8 (40)Coagulase negative (total)bS. epidermidis $152 (59)$ 49 (66)8 (40)S. warneri1 (0.4)0 (0.0)0 (0.0)S. capitis5 (1.9)0 (0.0)0 (0.0)S. caprae2 (0.8)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecium4 (2.0)3 (4.0)1 (5.0)Vher5 (2.0)3 (4.0)1 (5.0)Klebsiella $pneumoniae$ 4 (2.0)1 (1.0)pneumoniae4 (2.0)1 (1.0)1 (5.0)Serratia marcescens4 (2.0)1 (1.0)0 (0.0)Other4 (2.0)1 (1.0)0 (0.0)Gandida $albicans$ 8 (3.0)6 (8.0)1 (5.0)glabrata3 (1.0)2 (3.0)1 (5.0)glabrata3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	Gram positives:	216 (84)	66 (89)	16 (80)
Coagulase negative (total)bS. epidermidis $152 (59)$ $49 (66)$ $8 (40)$ S. warneri1 (0.4)0 (0.0)0 (0.0)S. capitis $5 (1.9)$ 0 (0.0)0 (0.0)S. caprae2 (0.8)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus $faecalis$ 3 (1.0)1 (1.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecium4 (2.0)3 (4.0)1 (5.0)Other5 (2.0)3 (4.0)1 (5.0)Klebsiella $meumoniae$ 4 (2.0)1 (1.0)pneumoniae4 (2.0)1 (1.0)1 (5.0)Secherichia coli3 (1.0)1 (1.0)0 (0.0)Gandida $albicans$ 8 (3.0)6 (8.0)1 (5.0)glabrata3 (1.0)2 (3.0)1 (5.0)parapsilosis3 (1.0)1 (1.0)0 (0.0)	Staphylococcus	164 (64)	49 (66)	8 (40)
S. epidermidis $152 (59)$ $49 (66)$ $8 (40)$ S. warneri1 (0.4)0 (0.0)0 (0.0)S. capitis5 (1.9)0 (0.0)0 (0.0)S. caprae2 (0.8)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus $faecalis$ 3 (1.0)1 (1.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecum4 (2.0)3 (4.0)1 (5.0)Other5 (2.0)3 (4.0)1 (5.0)Klebsiella $meumoniae$ 4 (2.0)1 (1.0)pneumoniae4 (2.0)1 (1.0)1 (5.0)Escherichia coli3 (1.0)1 (1.0)0 (0.0)Other4 (2.0)1 (1.0)0 (0.0)Qatada3 (1.0)1 (1.0)0 (0.0)feasts:19 (7.0)9 (12)2 (10)Candida3 (1.0)2 (3.0)1 (5.0)glabrata3 (1.0)2 (3.0)1 (5.0)parapsilosis3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	Coagulase negative (tota	l) <sup>b</sup>		
S. warneri1 (0.4)0 (0.0)0 (0.0)S. capitis5 (1.9)0 (0.0)0 (0.0)S. caprae2 (0.8)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus11 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecium4 (2.0)3 (4.0)1 (5.0)Other5 (2.0)3 (4.0)1 (5.0)Klebsiella $pneumoniae$ 4 (2.0)1 (1.0)0 (0.0)servatia marcescens4 (2.0)1 (1.0)0 (0.0)Other4 (2.0)1 (1.0)0 (0.0)Veasts:19 (7.0)9 (12)2 (10)Candida3 (1.0)1 (1.0)0 (0.0)glabrata3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	S. epidermidis	152 (59)	49 (66)	8 (40)
S. capitis $5(1.9)$ $0(0.0)$ $0(0.0)$ S. caprae $2(0.8)$ $0(0.0)$ $0(0.0)$ S. hominis $1(0.4)$ $0(0.0)$ $0(0.0)$ S. haemolyticus $1(0.4)$ $0(0.0)$ $0(0.0)$ S. simulans $1(0.4)$ $0(0.0)$ $0(0.0)$ S. lugdunensis $1(0.4)$ $0(0.0)$ $0(0.0)$ S. lugdunensis $1(0.4)$ $0(0.0)$ $0(0.0)$ S. lugdunensis $1(0.4)$ $0(0.0)$ $0(0.0)$ Staphylococcus aureus $32(12)$ $11(15)$ $7(35)$ other $8(3.0)$ $1(1.0)$ $0(0.0)$ Enterococcus $faecalis$ $3(1.0)$ $1(1.0)$ $0(0.0)$ faecalis $3(1.0)$ $1(1.0)$ $0(0.0)$ faecalis $3(1.0)$ $1(1.0)$ $0(0.0)$ Gram negatives: $22(9.0)$ $9(12)$ $2(10)$ Pseudomonas aeruginosa $5(2.0)$ $3(4.0)$ $1(5.0)$ Klebsiella $meumoniae$ $4(2.0)$ $1(1.0)$ $0(0.0)$ Serratia marcescens $4(2.0)$ $1(1.0)$ $0(0.0)$ Other $4(2.0)$ $1(1.0)$ $0(0.0)$ Veasts: $19(7.0)$ $9(12)$ $2(10)$ Candida $3(1.0)$ $1(1.0)$ $0(0.0)$ glabrata $3(1.0)$ $1(1.0)$ $0(0.0)$ other $5(2.0)$ $0(0.0)$ $0(0.0)$	S. warneri	1 (0.4)	0 (0.0)	0 (0.0)
S. caprae2 (0.8)0 (0.0)0 (0.0)S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus $3$ (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecium4 (2.0)3 (4.0)1 (5.0)Other5 (2.0)3 (4.0)1 (5.0)Rebeila $y$ $y$ $y$ $y$ pneumoniae4 (2.0)1 (1.0)0 (0.0)aerogenes2 (0.8)2 (3.0)0 (0.0)Serratia marcescens4 (2.0)1 (1.0)0 (0.0)Other4 (2.0)1 (1.0)0 (0.0)glabrata3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	S. capitis	5 (1.9)	0 (0.0)	0 (0.0)
S. hominis1 (0.4)0 (0.0)0 (0.0)S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus $3$ (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecium4 (2.0)3 (4.0)1 (5.0)Other5 (2)1 (1)0Gram negatives:22 (9.0)9 (12)2 (10)Pseudomonas aeruginosa5 (2.0)3 (4.0)1 (5.0)Klebsiella $1$ 1.0)0 (0.0)aerogenes2 (0.8)2 (3.0)0 (0.0)Serratia marcescens4 (2.0)1 (1.0)0 (0.0)Other4 (2.0)1 (1.0)0 (0.0)Gradida3 (1.0)1 (1.0)0 (0.0)Other5 (2.0)0 (0.0)0 (0.0)	S. caprae	2 (0.8)	0 (0.0)	0 (0.0)
S. haemolyticus1 (0.4)0 (0.0)0 (0.0)S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus $32$ (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus $3$ (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)Gram negatives:22 (9.0)9 (12)2 (10)Pseudomonas aeruginosa5 (2.0)3 (4.0)1 (5.0)Klebsiella $v$ $v$ $v$ pneumoniae4 (2.0)1 (1.0)0 (0.0)Serratia marcescens4 (2.0)1 (1.0)0 (0.0)Other4 (2.0)1 (1.0)0 (0.0)Veasts:19 (7.0)9 (12)2 (10)Candida3 (1.0)2 (3.0)1 (5.0)glabrata3 (1.0)2 (3.0)1 (5.0)parapsilosis3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	S. hominis	1 (0.4)	0 (0.0)	0 (0.0)
S. simulans1 (0.4)0 (0.0)0 (0.0)S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus $32$ (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus $3$ (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis5 (2.0)3 (4.0)1 (5.0)Other5 (2.0)3 (4.0)1 (5.0)Rebsiella $1$ $1$ $0$ pneumoniae4 (2.0)1 (1.0)0 (0.0)aerogenes2 (0.8)2 (3.0) $0$ (0.0)Serratia marcescens4 (2.0)1 (1.0) $0$ (0.0)Other4 (2.0)1 (1.0) $0$ (0.0)Other $4$ (2.0)1 (1.0) $0$ (0.0)Other $3$ (1.0)1 (1.0) $0$ (0.0)Other $3$ (1.0) $1$ (1.0) $0$ (0.0)glabrata $3$ (1.0) $1$ (1.0) $0$ (0.0)other $5$ (2.0) $0$ (0.0) $0$ (0.0)	S. haemolyticus	1 (0.4)	0 (0.0)	0 (0.0)
S. lugdunensis1 (0.4)0 (0.0)0 (0.0)Staphylococcus aureus32 (12)11 (15)7 (35)other8 (3.0)1 (1.0)0 (0.0)Enterococcus $faecalis$ 3 (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis3 (1.0)1 (1.0)0 (0.0)faecalis5 (2.0)3 (4.0)1 (5.0)Other5 (2.0)3 (4.0)1 (5.0)Rebsiella $5$ 2.0)3 (4.0)1 (5.0)pneumoniae4 (2.0)1 (1.0)0 (0.0)aerogenes2 (0.8)2 (3.0)0 (0.0)Serratia marcescens4 (2.0)1 (1.0)1 (5.0)Escherichia coli3 (1.0)1 (1.0)0 (0.0)Other4 (2.0)1 (1.0)0 (0.0)Quadida3 (1.0)1 (1.0)0 (0.0)albicans8 (3.0)6 (8.0)1 (5.0)glabrata3 (1.0)2 (3.0)1 (5.0)parapsilosis3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	S. simulans	1 (0.4)	0 (0.0)	0 (0.0)
Staphylococcus aureus other $32 (12)$ $11 (15)$ $7 (35)$ $8 (3.0)$ Enterococcus faecalis $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ Enterococcus faecalim $4 (2.0)$ $3 (4.0)$ $1 (5.0)$ Other $5 (2)$ $1 (1)$ $0$ Gram negatives: $22 (9.0)$ $9 (12)$ $2 (10)$ Pseudomonas aeruginosa klebsiella $5 (2.0)$ $3 (4.0)$ $1 (5.0)$ Klebsiella pneumoniae $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ Serratia marcescens $4 (2.0)$ $1 (1.0)$ $1 (5.0)$ Scherichia coli $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ Other $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ Serratia marcescens $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ Grandida $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ Other $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ Other $5 (2.0)$ $0 (0.0)$ $0 (0.0)$	S. lugdunensis	1 (0.4)	0 (0.0)	0 (0.0)
other $8 (3.0)$ $1 (1.0)$ $0 (0.0)$ Enterococcusfaecalis $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ faecalis $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ faecalis $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ faecium $4 (2.0)$ $3 (4.0)$ $1 (5.0)$ Other $5 (2)$ $1 (1)$ $0$ Gram negatives:22 (9.0) $9 (12)$ $2 (10)$ Pseudomonas aeruginosa $5 (2.0)$ $3 (4.0)$ $1 (5.0)$ Klebsiella $0 (0.0)$ $2 (3.0)$ $0 (0.0)$ aerogenes $2 (0.8)$ $2 (3.0)$ $0 (0.0)$ Serratia marcescens $4 (2.0)$ $1 (1.0)$ $1 (5.0)$ Escherichia coli $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ Other $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ Veasts: $19 (7.0)$ $9 (12)$ $2 (10)$ Candida $3 (1.0)$ $2 (3.0)$ $1 (5.0)$ glabrata $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ other $5 (2.0)$ $0 (0.0)$ $0 (0.0)$	Staphylococcus aureus	32 (12)	11 (15)	7 (35)
Enterococcusfaecalis $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ faecium $4 (2.0)$ $3 (4.0)$ $1 (5.0)$ Other $5 (2)$ $1 (1)$ $0$ Gram negatives: $22 (9.0)$ $9 (12)$ $2 (10)$ Pseudomonas aeruginosa $5 (2.0)$ $3 (4.0)$ $1 (5.0)$ Klebsiella $ -$ pneumoniae $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ aerogenes $2 (0.8)$ $2 (3.0)$ $0 (0.0)$ Serratia marcescens $4 (2.0)$ $1 (1.0)$ $1 (5.0)$ Escherichia coli $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ Other $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ Gandida $  -$ albicans $8 (3.0)$ $6 (8.0)$ $1 (5.0)$ glabrata $3 (1.0)$ $2 (3.0)$ $1 (5.0)$ parapsilosis $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ other $5 (2.0)$ $0 (0.0)$ $0 (0.0)$	other	8 (3.0)	1 (1.0)	0 (0.0)
faecalis       3 (1.0)       1 (1.0)       0 (0.0)         faecium       4 (2.0)       3 (4.0)       1 (5.0)         Other       5 (2)       1 (1)       0         Gram negatives:       22 (9.0)       9 (12)       2 (10)         Pseudomonas aeruginosa       5 (2.0)       3 (4.0)       1 (5.0)         Klebsiella       7       7       9 (12)       2 (10)         pneumoniae       4 (2.0)       1 (1.0)       0 (0.0)         aerogenes       2 (0.8)       2 (3.0)       0 (0.0)         Serratia marcescens       4 (2.0)       1 (1.0)       1 (5.0)         Escherichia coli       3 (1.0)       1 (1.0)       0 (0.0)         Other       4 (2.0)       1 (1.0)       0 (0.0)         Other       9 (7.0)       9 (12)       2 (10)         Candida       3 (1.0)       2 (3.0)       1 (5.0)         glabrata       3 (1.0)       2 (3.0)       1 (5.0)         parapsilosis       3 (1.0)       1 (1.0)       0 (0.0)	Enterococcus			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	faecalis	3 (1.0)	1 (1.0)	0 (0.0)
Other $5 (2)$ $1 (1)$ $0$ Gram negatives: $22 (9.0)$ $9 (12)$ $2 (10)$ Pseudomonas aeruginosa $5 (2.0)$ $3 (4.0)$ $1 (5.0)$ Klebsiella $v$ $v$ $v$ $v$ pneumoniae $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ aerogenes $2 (0.8)$ $2 (3.0)$ $0 (0.0)$ Serratia marcescens $4 (2.0)$ $1 (1.0)$ $1 (5.0)$ Escherichia coli $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ Other $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ Yeasts: $19 (7.0)$ $9 (12)$ $2 (10)$ Candida $3 (1.0)$ $2 (3.0)$ $1 (5.0)$ glabrata $3 (1.0)$ $2 (3.0)$ $1 (5.0)$ parapsilosis $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ other $5 (2.0)$ $0 (0.0)$ $0 (0.0)$	faecium	4 (2.0)	3 (4.0)	1 (5.0)
Gram negatives: Pseudomonas aeruginosa $22 (9.0)$ $5 (2.0)$ $9 (12)$ $3 (4.0)$ $2 (10)$ $1 (5.0)$ Rebsiella $5 (2.0)$ $3 (4.0)$ $1 (5.0)$ pneumoniae $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ $aerogenes$ $2 (0.8)$ $2 (3.0)$ $0 (0.0)$ Serratia marcescens $4 (2.0)$ $1 (1.0)$ $1 (5.0)$ Escherichia coli $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ Other $4 (2.0)$ $1 (1.0)$ $0 (0.0)$ Yeasts: $19 (7.0)$ $9 (12)$ $2 (10)$ Candida $3 (1.0)$ $2 (3.0)$ $1 (5.0)$ glabrata $3 (1.0)$ $2 (3.0)$ $1 (5.0)$ parapsilosis $3 (1.0)$ $1 (1.0)$ $0 (0.0)$ other $5 (2.0)$ $0 (0.0)$ $0 (0.0)$	Other	5 (2)	1 (1)	0
Pseudomonas aeruginosa         5 (2.0)         3 (4.0)         1 (5.0)           Klebsiella             1 (5.0)           pneumoniae         4 (2.0)         1 (1.0)         0 (0.0)             aerogenes         2 (0.8)         2 (3.0)         0 (0.0)              Serratia marcescens         4 (2.0)         1 (1.0)         1 (5.0) <td>Gram negatives:</td> <td>22 (9.0)</td> <td>9 (12)</td> <td>2 (10)</td>	Gram negatives:	22 (9.0)	9 (12)	2 (10)
Klebsiella         pneumoniae       4 (2.0)       1 (1.0)       0 (0.0)         aerogenes       2 (0.8)       2 (3.0)       0 (0.0)         Serratia marcescens       4 (2.0)       1 (1.0)       1 (5.0)         Escherichia coli       3 (1.0)       1 (1.0)       0 (0.0)         Other       4 (2.0)       1 (1.0)       0 (0.0)         Yeasts:       19 (7.0)       9 (12)       2 (10)         Candida       3 (1.0)       2 (3.0)       1 (5.0)         glabrata       3 (1.0)       2 (3.0)       1 (5.0)         parapsilosis       3 (1.0)       1 (1.0)       0 (0.0)         other       5 (2.0)       0 (0.0)       0 (0.0)	Pseudomonas aeruginosa	5 (2.0)	3 (4.0)	1 (5.0)
pneumoniae         4 (2.0)         1 (1.0)         0 (0.0)           aerogenes         2 (0.8)         2 (3.0)         0 (0.0)           Serratia marcescens         4 (2.0)         1 (1.0)         1 (5.0)           Escherichia coli         3 (1.0)         1 (1.0)         0 (0.0)           Other         4 (2.0)         1 (1.0)         0 (0.0)           Yeasts:         19 (7.0)         9 (12)         2 (10)           Candida	Klebsiella			
aerogenes         2 (0.8)         2 (3.0)         0 (0.0)           Serratia marcescens         4 (2.0)         1 (1.0)         1 (5.0)           Escherichia coli         3 (1.0)         1 (1.0)         0 (0.0)           Other         4 (2.0)         1 (1.0)         0 (0.0)           Yeasts:         19 (7.0)         9 (12)         2 (10)           Candida	pneumoniae	4 (2.0)	1 (1.0)	0 (0.0)
Serratia marcescens         4 (2.0)         1 (1.0)         1 (5.0)           Escherichia coli         3 (1.0)         1 (1.0)         0 (0.0)           Other         4 (2.0)         1 (1.0)         0 (0.0)           Yeasts:         19 (7.0)         9 (12)         2 (10)           Candida	aerogenes	2 (0.8)	2 (3.0)	0 (0.0)
Escherichia coli         3 (1.0)         1 (1.0)         0 (0.0)           Other         4 (2.0)         1 (1.0)         0 (0.0)           Yeasts:         19 (7.0)         9 (12)         2 (10)           Candida         albicans         8 (3.0)         6 (8.0)         1 (5.0)           glabrata         3 (1.0)         2 (3.0)         1 (5.0)           parapsilosis         3 (1.0)         1 (1.0)         0 (0.0)           other         5 (2.0)         0 (0.0)         0 (0.0)	Serratia marcescens	4 (2.0)	1 (1.0)	1 (5.0)
Other         4 (2.0)         1 (1.0)         0 (0.0)           Yeasts:         19 (7.0)         9 (12)         2 (10)           Candida	Escherichia coli	3 (1.0)	1 (1.0)	0 (0.0)
Yeasts:19 (7.0)9 (12)2 (10)Candidaalbicans8 (3.0)6 (8.0)1 (5.0)glabrata3 (1.0)2 (3.0)1 (5.0)parapsilosis3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	Other	4 (2.0)	1 (1.0)	0 (0.0)
Candidaalbicans8 (3.0)6 (8.0)1 (5.0)glabrata3 (1.0)2 (3.0)1 (5.0)parapsilosis3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	Yeasts:	19 (7.0)	9 (12)	2 (10)
albicans8 (3.0)6 (8.0)1 (5.0)glabrata3 (1.0)2 (3.0)1 (5.0)parapsilosis3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	Candida			
glabrata3 (1.0)2 (3.0)1 (5.0)parapsilosis3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	albicans	8 (3.0)	6 (8.0)	1 (5.0)
parapsilosis3 (1.0)1 (1.0)0 (0.0)other5 (2.0)0 (0.0)0 (0.0)	glabrata	3 (1.0)	2 (3.0)	1 (5.0)
other 5 (2.0) 0 (0.0) 0 (0.0)	parapsilosis	3 (1.0)	1 (1.0)	0 (0.0)
	other	5 (2.0)	0 (0.0)	0 (0.0)

<sup>a</sup> Numbers are presented as number (%). Registering multiple pathogens for one CVC tip was possible.

<sup>b</sup> Coagulase negative staphylococci were type speciated using the MALDI-TOF technique.

of CVC infections at the studied hospitals. S. *epidermidis* has previously been described as the most common coagulase negative staphylococcus species in CRI [17]. In the present study, S. *epidermidis* was the only coagulase negative staphylococcus responsible for CRI and CRBSI. When comparing these results with previous national studies on CRI [7,18], we observe regional differences in pathogen growth. Hence, these findings could impact local infection management strategies to prevent certain pathogens from causing CRI. As an example, antifungal treatment could be considered when treating suspected CVC infections in regions with higher incidences of CRI caused by *Candida* spp.

In the logistic regression analysis (Table V), we identified associations between independent variables and catheter tip colonisation as well as CRI. First, longer catheterisation times

### Table IV

Univariate analysis of potential risk factors for central venous catheter (CVC) tip colonisation and catheter-related infection (CRI). Data from between March 2019 and August 2020 in Region Skåne, Sweden<sup>a</sup>

Independent variables	Tip colonisation			CRI		
	Tip colonisation (n=257)	95% CI	P-value	CRI (n=74)	95% CI	P-value
Age	66 [56-75]	0.99-1.01	0.832	65 [57–75]	0.98-1.01	0.786
Sex, male	173 (67)	1.03-1.74	0.032	54 (73)	1.04-2.92	0.034
Days with catheter	8 [2—14]	1.01-1.02	0.002	6 [1–11]	0.98-1.02	0.985
Central Haemodialysis Catheter vs Central	23 (9.0)	1.43-3.44	<0.001	8 (11)	1.28-5.62	0.009
Venous Catheter						
Catheter lumens	-	1.41-1.72	<0.001	4 [3–5]	1.58-2.31	<0.001
Insertion site						
Jugular vein (reference)	236 (92)	-	-	-	-	-
Subclavian vein	17 (6.5)	0.27-0.74	0.001	5 (7.0)	0.18-1.13	0.090
Femoral vein	4 (1.5)	0.26-1.96	0.520	0 (0.0)	-	0.995
Anticoagulant treatment before insertion <sup>b</sup>	197 (77)	1b05-1.89	0.023	59 (80)	0.66-2.06	0.601
Procoagulant treatment before insertion	218 (85)	0.82-1.64	0.398	63 (85)	0.59-2.15	0.711
Room intended for CVC insertion						
Operating theatre (reference)	96 (38)	-	-	-	-	-
Intensive Care Unit	112 (44)	1.86-3.24	<0.001	37 (50)	1.91-5.35	<0.001
Room reserved for CVC-insertion	34 (13)	0.98-2.15	0.066	6 (8.0)	0.41-2.48	0.975
Patient ward	12 (5.0)	1.30-4.41	0.005	5 (7.0)	1.49-10.38	0.006
Department of admission at CVC insertion						
Surgical ward (reference)	83 (34)	-	-	-	-	-
Medical ward	82 (33)	1.27-2.36	<0.001	20 (27)	0.83-2.76	0.178
Intensive Care Unit	81 (33)	2.30-4.29	<0.001	27 (36)	2.11-6.46	<0.001
High risk patient <sup><math>c</math></sup>	90 (35)	1.50-2.53	<0.001	29 (39)	1.44-3.70	<0.001
Number of skin punctures		0.68-1.03	0.099	-	0.58-1.26	0.431
Number of punctured blood vessels		0.71-1.15	0.419	-	0.65-1.49	0.921
Immediate mechanical complications						
No (reference)	243 (95)	-	-	-	-	-
Bleeding/punctured artery	6 (2.0)	0.66-2.75	0.422	2 (3.0)	0.28-4.74	0.841
Other	8 (3.0)	0.43-2.23	0.962	2 (3.0)	0.28-4.66	0.860

<sup>a</sup> Numbers are presented as number (%) and continuous variables are presented as median [interquartile range].

<sup>b</sup> Warfarin and Non-vitamin K Antagonist Oral Anticoagulants were categorized as anticoagulative treatment, while Low Molecular Weight Heparin and Acetylsalicylic Acid were not.

<sup>c</sup> Immunocompromised patients.

were associated with catheter tip colonisation, but not with CRI. Previous studies have convincingly demonstrated that the time with the catheter correlates positively with the risk of CRI and CRBSI [7,18]. As noted by Hammarskjöld *et al.*, adequate adherence to routines advocating early removal of unnecessary catheters could minimize the effect of correlations between catheterisation time and CRI [7]. It has been suggested that catheter tip colonisation is a predisposal factor for CRI and CRBSI, hence we suggest that common practice should continue to prioritise the immediate removal of unnecessary CVCs [19]. Moreover, the current study demonstrates that CVCs inserted in the subclavian vein were associated with less catheter tip colonisation compared to insertion in the jugular vein. The insertion site, however, was not confirmed to affect the risk of CRI in this study.

Secondly, our results show that male sex and increased number of catheter lumens were associated with both catheter tip colonisation and CRI. Increased risk of catheter tip colonisation in men has previously been demonstrated in a retrospective study from 2008 by Gowardman *et al.* [16]. Studies linking gender to risk of CRI, however, are scarce. In a prospective study by Moro *et al.*, it was shown that men present an increased risk for skin colonisation at the CVC insertion site, which showed an increased risk of CRI, especially when using the jugular vein as point of insertion [20]. Furthermore, beard growth and shaving may not only facilitate pathogen multiplication, but has also been observed to reduce adherence of wound dressing materials, suggesting increased risk of bacterial contamination [21]. Increased number of CVC lumens being an associated risk factor for CRI has previously been reported [4,22], thus advocating for minimising the number of catheter lumens when choosing a CVC.

Thirdly, our results also indicate that CVCs inserted in patients admitted to a medical ward present an increased likelihood of catheter colonisation, when compared with patients admitted to a surgical ward. Several studies have evaluated the rates of CRI among inpatients receiving CVCs,

Table V

Multivariable logistic regression analyses for tip colonisation and catheter-related infection (CRI)<sup>a</sup>

Independent variables	Tip colonisation			CRI		
_	Odds Ratio	95% CI	P-value	Odds Ratio	95% CI	P-value
Age	1.01	0.99-1.01	0.676	1.01	0.98-1.02	0.876
Sex, male	1.50	1.11-2.04	0.008	2.06	1.13-3.78	0.019
Days with catheter	1.02	1.01-1.03	<0.001	1.02	0.99-1.04	0.130
Catheter lumens	1.57	1.37-1.80	<0.001	1.95	1.54-2.47	<0.001
Insertion site						
Jugular vein (reference)	-	-	-	-	-	-
Subclavian vein	0.36	0.21-0.63	<0.001	0.37	0.13-1.04	0.059
Femoral vein	0.42	0.10-1.73	0.070	-	-	0.996
Room intended for CVC insertion						
Operating theatre	0.68	0.45-1.03	0.071	0.62	0.30-1.27	0.190
High risk patient <sup>b</sup>	0.83	0.54-1.28	0.397	0.71	0.33-1.51	0.371
Department of admission at CVC insertion						
Surgical ward (reference)	-	-	-			
Medical ward	1.49	1.02-2.18	0.037			
Intensive Care Unit	1.18	0.72-1.95	0.511			
Anticoagulant treatment before insertion <sup>c</sup>	1.35	0.98-1.88	0.070			
Immediate mechanical complications						
No (reference)	-	-	-			
Bleeding/punctured artery	0.67	0.21-2.16	0.507			
Other	1.00	0.43-2.31	0.999			

<sup>a</sup> Abbreviations: catheter related infections (CRI), central venous catheter (CVC).

<sup>b</sup> Immunocompromised patients.

<sup>c</sup> Warfarin and NOACs were categorized as anticoagulative treatment, while Low Molecular Weight Heparin and Acetylsalicylic Acid were not.

with varying results [23]. As summarised by Kallen *et al.*, the differences in infection rates in different units can vary depending on the type of unit and teaching status of the facility [23]. In the light of this, it is more likely that the cause of the association between CVCs inserted in patients admitted to a medical ward and catheter tip colonisation is driven by a risk of bias in the selection of patients, where patients admitted to medical wards tend to be more immunocompromised and therefore more susceptible to infection.

By comparing this current study with previously conducted studies from the same region [4,24], it was used as a follow-up study on local CVC management. The results showed a sustained low CRI incidence. Hence, the study served as a quality improvement report indicating continuous safe CVC-routines in the studied region. Nevertheless, a low incidence is still not equal to zero and complete eradication of CRI should be the goal of any future interventions. As previously shown by Longmate *et al.* [5], rigorous hygiene and educational interventions can lead to complete elimination of CRI. Hence, a vision zero for CRI should be adopted as an ethical stance as it has been demonstrated possible to eradicate completely [25]. However, as part of an eradication process, CRI incidence should be evaluated longitudinally. Therefore, we need to find an efficient and systematic way to assess CRI over time.

In our study, as well as in more recent epidemiological studies on CRI and sepsis, but also generally, search queries and automatic script-based data extraction seems to be an efficient way of tracking medical device management and infection incidences [8-11,26]. As an example, Gokhale *et al.* 

recently presented a tool used for automatic data extraction for epidemiological research, using a process that can be verified and reproducible [26]. The study highlights how this new process of extracting available information reduces the gap between medical researchers and electronic records, enabling continuous quality surveillance.

Given that EHR (electronic health records) are increasingly used in healthcare systems for documentation, the potential power of the fully automated surveillance systems is yet to be discovered and evaluated. Data from EHRs has the potential to replace time consuming and subjective manual chart reviewsurveillance and may also provide continuous surveillance, such as in this study, which is the first one to our knowledge applying it to follow-up previous results. The automated electronic surveillance systems must be carefully evaluated, and the construction of the systems is resource consuming but once implemented, these systems have the potential to provide invaluable real-time quality assurance, superior to current standard. However, further research in this area, where we examine data abstraction methods across hospitals and validate automated data extraction systems, are still needed [27].

We recognise the limitations in the present study given the retrospective design. Although there is a strong tradition in the studied departments to document every CVC-insertion, it cannot be ruled out that single insertions were not documented. Although, we have tried to correct for confounders in the multivariable logistic regression analyses and the goodness of fit test was good, the presence of occult independent

#### Table VI

Characteristics of patients with confirmed catheter related bloodstream infection  $\left(\text{CRBSI}\right)^a$ 

(n=9904)         (n=20)           Age         69 [57-76]         66 [53-71]           Sex, male         6027 (61)         11 (55)           Days with catheter         5 [2-10]         6 [1-15]           Central Haemodialysis Catheter         430 (4.0)         4 (20)           vs Central Venous Catheter         2         2 (10)           2         2186 (22)         3 (15)           3         2793 (28)         2 (10)           4         666 (7.0)         0 (0.0)           5         994 (10)         9 (45)           Insertion site	Variable	No CRBSI	CRBSI
Age69 $[57-76]$ 66 $[53-71]$ Sex, male6027 (61)11 (55)Days with catheter5 $[2-10]$ 6 $[1-15]$ Central Haemodialysis Catheter430 (4.0)4 (20)vs Central Venous Catheter22Catheter lumens2212645 (27)2 (10)22186 (22)3 (15)32793 (28)2 (10)4666 (7.0)0 (0.0)5994 (10)9 (45)Insertion siteJugular vein8381 (85)17 (85)Subclavian vein1327 (13)3 (15)Femoral vein196 (2.0)0 (0.0)Anticoagulant treatment at8127 (82)16 (80)insertionProcoagulant treatment at8577 (87)17 (85)before insertionPoperating theatre5336 (54)3 (15)Intensive Care Unit2604 (26)12 (60)Room reserved for CVC1321 (13)2 (10)insertionPatient ward286 (3.0)2 (10)Patient ward286 (3.0)2 (10)Department of admission at CVC insertion9 (45)Intensive Care Unit1615 (16)9 (45)High risk patients2159 (22)10 (50)Number of skin punctures17450 (75)17450 (75)18 (90)21369 (14)1 (5.0)3361 (4.0)0 (0.0)520 (0.2)0 (0.0)520 (0.2)0 (0.0)520 (0.2)0 (0.0)1 <td></td> <td>(n=9904)</td> <td>(n=20)</td>		(n=9904)	(n=20)
Sex, male $602^{7}$ (61)       11 (55)         Days with catheter       5 [2-10]       6 [1-15]         Central Haemodialysis Catheter       430 (4.0)       4 (20)         vs Central Venous Catheter       2       1         Catheter lumens       2       1(5)         1       2645 (27)       2 (10)         2       2186 (22)       3 (15)         3       2793 (28)       2 (10)         4       666 (7.0)       0 (0.0)         5       994 (10)       9 (45)         Insertion site       Jugular vein       8381 (85)       17 (85)         Subclavian vein       1327 (13)       3 (15)       Femoral vein       196 (2.0)       0 (0.0)         Anticoagulant treatment at       8127 (82)       16 (80)       insertion         Procoagulant treatment at       8127 (87)       17 (85)       before insertion         Room intended for CVC insertion       Operating theatre       5336 (54)       3 (15)         Intensive Care Unit       2604 (26)       12 (60)       Room reserved for CVC insertion         Surgical ward       286 (3.0)       2 (10)       insertion         Patient ward       286 (3.0)       2 (10)         Intensive Care Unit	Age	69 [57-76]	66 [53-71]
Days with catheter         5 [2-10]         6 [1-15]           Central Haemodialysis Catheter         430 (4.0)         4 (20)           vs Central Venous Catheter         2         30 (4.0)         4 (20)           Catheter lumens         2         1         2645 (27)         2 (10)           1         2645 (27)         2 (10)         3 (15)         3           3         2793 (28)         2 (10)         4         666 (7.0)         0 (0.0)           5         994 (10)         9 (45)         945         1           Insertion site         Jugular vein         8381 (85)         17 (85)           Subclavian vein         1327 (13)         3 (15)         5           Femoral vein         196 (2.0)         0 (0.0)           Anticoagulant treatment at         8127 (82)         16 (80)           insertion	Sex, male	6027 (61)	11 (55)
Central Haemodialysis Catheter         430 (4.0)         4 (20)           vs Central Venous Catheter         2           Catheter lumens         2           1         2645 (27)         2 (10)           2         2186 (22)         3 (15)           3         2793 (28)         2 (10)           4         666 (7.0)         0 (0.0)           5         994 (10)         9 (45)           Insertion site         Jugular vein         8381 (85)         17 (85)           Subclavian vein         1327 (13)         3 (15)           Femoral vein         196 (2.0)         0 (0.0)           Anticoagulant treatment at         8127 (87)         17 (85)           before insertion         Procoagulant treatment at         8577 (87)         17 (85)           before insertion         Operating theatre         5336 (54)         3 (15)           Intensive Care Unit         2604 (26)         12 (60)           Room reserved for CVC         1321 (13)         2 (10)           insertion         Patient ward         286 (3.0)         2 (10)           Patient ward         286 (3.0)         2 (10)         Operating theatre           Surgical ward         5042 (51)         3 (15)	Days with catheter	5 [2-10]	6 [1–15]
vs Central Venous Catheter         Catheter lumens         1       2645 (27)       2 (10)         2       2186 (22)       3 (15)         3       2793 (28)       2 (10)         4       666 (7.0)       0 (0.0)         5       994 (10)       9 (45)         Insertion site         Jugular vein       8381 (85)       17 (85)         Subclavian vein       1327 (13)       3 (15)         Femoral vein       196 (2.0)       0 (0.0)         Anticoagulant treatment at 8127 (82)       16 (80)         insertion         Procoagulant treatment       8577 (87)       17 (85)         before insertion         Room intended for CVC insertion         Operating theatre       5336 (54)       3 (15)         Intensive Care Unit       2604 (26)       12 (60)         Room reserved for CVC       1321 (13)       2 (10)         insertion       2       2       16         Surgical ward       2042 (51)       3 (15)         Medical ward       2905 (29)       5 (25)         Intensive Care Unit       1615 (16)       9 (45)	Central Haemodialysis Catheter	430 (4.0)	4 (20)
Catheter lumens         1       2645 (27)       2 (10)         2       2186 (22)       3 (15)         3       2793 (28)       2 (10)         4       666 (7.0)       0 (0.0)         5       994 (10)       9 (45)         Insertion site       Jugular vein       8381 (85)       17 (85)         Subclavian vein       1327 (13)       3 (15)         Femoral vein       196 (2.0)       0 (0.0)         Anticoagulant treatment at       8127 (82)       16 (80)         insertion       Procoagulant treatment at       8577 (87)       17 (85)         before insertion       Procoagulant treatment at       8577 (87)       17 (85)         Deparating theatre       5336 (54)       3 (15)       Intensive Care Unit       2604 (26)       12 (60)         Room reserved for CVC       1321 (13)       2 (10)       Department of admission at CVC insertion       Surgical ward       5042 (51)       3 (15)         Medical ward       2905 (29)       5 (25)       Intensive Care Unit       1615 (16)       9 (45)         High risk patients       2159 (22)       10 (50)       Number of skin punctures       1       1       7450 (75)       18 (90)       2       1615 (16) <t< td=""><td>vs Central Venous Catheter</td><td></td><td></td></t<>	vs Central Venous Catheter		
1       2645 (27)       2 (10)         2       2186 (22)       3 (15)         3       2793 (28)       2 (10)         4       666 (7.0)       0 (0.0)         5       994 (10)       9 (45)         Insertion site       Jugular vein       8381 (85)       17 (85)         Subclavian vein       1327 (13)       3 (15)         Femoral vein       196 (2.0)       0 (0.0)         Anticoagulant treatment at       8127 (82)       16 (80)         insertion       17 (85)       5         Percoagulant treatment at       8127 (82)       16 (80)         insertion       7       7       7         Procoagulant treatment       8577 (87)       17 (85)         before insertion       7       7       7         Operating theatre       5336 (54)       3 (15)         Intensive Care Unit       2604 (26)       12 (60)         Room reserved for CVC       1321 (13)       2 (10)         Department of admission at CVC insertion       5       255         Intensive Care Unit       1615 (16)       9 (45)         High risk patients       2159 (22)       10 (50)         Number of skin punctures       1       1545 (	Catheter lumens		
2       2186 (22)       3 (15)         3       2793 (28)       2 (10)         4       666 (7.0)       0 (0.0)         5       994 (10)       9 (45)         Insertion site	1	2645 (27)	2 (10)
3       2793 (28)       2 (10)         4       666 (7.0)       0 (0.0)         5       994 (10)       9 (45)         Insertion site       Jugular vein       8381 (85)       17 (85)         Subclavian vein       1327 (13)       3 (15)         Femoral vein       196 (2.0)       0 (0.0)         Anticoagulant treatment at       8127 (82)       16 (80)         insertion       Procoagulant treatment at       8577 (87)       17 (85)         before insertion       Room intended for CVC insertion       0       2 (60)         Room reserved for CVC       1321 (13)       2 (10)       1         insertion       Patient ward       286 (3.0)       2 (10)         Department of admission at CVC insertion       Surgical ward       5042 (51)       3 (15)         Medical ward       2905 (29)       5 (25)       1         Intensive Care Unit       1615 (16)       9 (45)         High risk patients       2159 (22)       10 (00)         Number of skin punctures       1       7450 (75)       18 (90)         2       1545 (16)       1 (5.0)       3       516 (5.0)       0 (0.0)         4       122 (1.0)       0 (0.0)       5 or more       60 (	2	2186 (22)	3 (15)
4       666 (7.0)       0 (0.0)         5       994 (10)       9 (45)         Insertion site       Jugular vein       8381 (85)       17 (85)         Subclavian vein       1327 (13)       3 (15)         Femoral vein       196 (2.0)       0 (0.0)         Anticoagulant treatment at       8127 (82)       16 (80)         insertion       Procoagulant treatment at       8577 (87)       17 (85)         before insertion       Procoagulant treatment       8577 (87)       17 (85)         before insertion       Operating theatre       5336 (54)       3 (15)         Intensive Care Unit       2604 (26)       12 (60)         Room reserved for CVC       1321 (13)       2 (10)         insertion       Patient ward       286 (3.0)       2 (10)         Department of admission at CVC insertion       Surgical ward       2905 (29)       5 (25)         Intensive Care Unit       1615 (16)       9 (45)         High risk patients       2159 (22)       10 (50)         Number of skin punctures       I       7450 (75)       18 (90)         2       1545 (16)       1 (5.0)       3       516 (5.0)       0 (0.0)         5 or more       60 (1.0)       0 (0.0)	3	2793 (28)	2 (10)
5         994 (10)         9 (45)           Insertion site         Jugular vein         8381 (85)         17 (85)           Subclavian vein         1327 (13)         3 (15)           Femoral vein         196 (2.0)         0 (0.0)           Anticoagulant treatment at         8127 (82)         16 (80)           insertion             Procoagulant treatment         8577 (87)         17 (85)           before insertion             Room intended for CVC insertion          12 (60)           Room reserved for CVC         1321 (13)         2 (10)           insertion          2 (10)           neserved for CVC         1321 (13)         2 (10)           Department of admission at CVC insertion          2 (10)           Surgical ward         2 86 (3.0)         2 (10)           Department of admission at CVC insertion          5 (25)           Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2 159 (22)         10 (50)           Number of skin punctures         1         1 (5.0)           3         516 (5.0)         0 (0.0)           4         122 (1.0)	4	666 (7.0)	0 (0.0)
Insertion site           Jugular vein         8381 (85)         17 (85)           Subclavian vein         1327 (13)         3 (15)           Femoral vein         196 (2.0)         0 (0.0)           Anticoagulant treatment at         8127 (82)         16 (80)           insertion         8577 (87)         17 (85)           before insertion         8577 (87)         17 (85)           before insertion         8577 (87)         17 (85)           com intended for CVC insertion         0         12 (60)           Room intended for CVC         1321 (13)         2 (10)           ninsertion         2604 (26)         12 (60)           Room reserved for CVC         1321 (13)         2 (10)           oinsertion         9         2 (10)           Patient ward         286 (3.0)         2 (10)           Department of admission at CVC insertion         5         3 (15)           Medical ward         2905 (29)         5 (25)           Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)           Number of skin punctures         1         1 (5.0)           3         516 (5.0)         0 (0.0)           <	5	994 (10)	9 (45)
Jugular vein         8381 (85)         17 (85)           Subclavian vein         1327 (13)         3 (15)           Femoral vein         196 (2.0)         0 (0.0)           Anticoagulant treatment at         8127 (82)         16 (80)           insertion         If (85)         17 (85)           Procoagulant treatment         8577 (87)         17 (85)           before insertion         Femoral vein         12 (82)           Room intended for CVC insertion         Operating theatre         5336 (54)         3 (15)           Intensive Care Unit         2604 (26)         12 (60)         Room reserved for CVC         1321 (13)         2 (10)           insertion         Patient ward         286 (3.0)         2 (10)         Department of admission at CVC insertion           Surgical ward         5042 (51)         3 (15)         Medical ward         2905 (29)         5 (25)           Intensive Care Unit         1615 (16)         9 (45)         14           High risk patients         2159 (22)         10 (50)           Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3         516 (5.0)         0 (0.0)           4         122 (1.0)	Insertion site		
Subclavian vein         1327 (13)         3 (15)           Femoral vein         196 (2.0)         0 (0.0)           Anticoagulant treatment at         8127 (82)         16 (80)           insertion         Insertion         Insertion           Procoagulant treatment         8577 (87)         17 (85)           before insertion         Operating theatre         5336 (54)         3 (15)           Intensive Care Unit         2604 (26)         12 (60)           Room reserved for CVC         1321 (13)         2 (10)           insertion         Patient ward         286 (3.0)         2 (10)           Department of admission at CVC insertion         Surgical ward         5042 (51)         3 (15)           Medical ward         2905 (29)         5 (25)         Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)         Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)         5 or more         60 (1.0)         0 (0.0)           5         0 (36) (14)         1 (5.0)         3         361 (4.0)	Jugular vein	8381 (85)	17 (85)
Femoral vein       196 (2.0)       0 (0.0)         Anticoagulant treatment at       8127 (82)       16 (80)         insertion       Procoagulant treatment       8577 (87)       17 (85)         before insertion       Room intended for CVC insertion       12 (60)         Room reserved for CVC       1321 (13)       2 (10)         insertion       2604 (26)       12 (60)         Room reserved for CVC       1321 (13)       2 (10)         insertion       286 (3.0)       2 (10)         Patient ward       286 (3.0)       2 (10)         Department of admission at CVC insertion       Surgical ward       5042 (51)       3 (15)         Medical ward       2905 (29)       5 (25)       1         Intensive Care Unit       1615 (16)       9 (45)         High risk patients       2159 (22)       10 (50)         Number of skin punctures       1       7450 (75)       18 (90)         2       1545 (16)       1 (5.0)       3       516 (5.0)       0 (0.0)         4       122 (1.0)       0 (0.0)       60 (1.0)       0 (0.0)       60 (1.0)       0 (0.0)         5 or more       60 (1.0)       0 (0.0)       165.0)       0 (0.0)       160 (0.0)       160 (0.0)	Subclavian vein	1327 (13)	3 (15)
Anticoagulant treatment at       \$127 (82)       16 (80)         insertion       Procoagulant treatment       \$577 (87)       17 (85)         before insertion       Room intended for CVC insertion       0perating theatre       5336 (54)       3 (15)         Intensive Care Unit       2604 (26)       12 (60)       Room reserved for CVC       1321 (13)       2 (10)         insertion       286 (3.0)       2 (10)       10       10         Patient ward       286 (3.0)       2 (10)       2 (10)         Department of admission at CVC insertion       Surgical ward       5042 (51)       3 (15)         Medical ward       2905 (29)       5 (25)       10 (50)         Number of skin punctures       1       7450 (75)       18 (90)         2       1545 (16)       1 (5.0)       3         3       516 (5.0)       0 (0.0)         4       122 (1.0)       0 (0.0)         5 or more       60 (1.0)       0 (0.0)         4       122 (1.0)       0 (0.0)         5 or more       60 (1.0)       0 (0.0)         5 or more       60 (1.0)       0 (0.0)         3       361 (4.0)       0 (0.0)         4       59 (1.0)       0 (0.0)	Femoral vein	196 (2.0)	0 (0.0)
insertion           Procoagulant treatment         8577 (87)         17 (85)           before insertion         Room intended for CVC insertion         3 (15)           Intensive Care Unit         2604 (26)         12 (60)           Room reserved for CVC         1321 (13)         2 (10)           insertion         Patient ward         286 (3.0)         2 (10)           Department of admission at CVC insertion         Surgical ward         5042 (51)         3 (15)           Medical ward         2905 (29)         5 (25)         1           Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)           Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3           3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)           5 or more         60 (1.0)         0 (0.0)           5 or more         60 (1.0)         0 (0.0)           4         122 (1.0)         0 (0.0)           5 or more         60 (1.0)         0 (0.0)           4         165 (16)         1 (5.0)           3	Anticoagulant treatment at	8127 (82)	16 (80)
Procoagulant treatment         8577 (87)         17 (85)           before insertion         Room intended for CVC insertion         3 (15)           Intensive Care Unit         2604 (26)         12 (60)           Room reserved for CVC         1321 (13)         2 (10)           insertion         286 (3.0)         2 (10)           Patient ward         286 (3.0)         2 (10)           Department of admission at CVC insertion         3 (15)           Medical ward         2905 (29)         5 (25)           Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)           Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3           3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)           5 or more         60 (1.0)         0 (0.0)           2         1369 (14)         1 (5.0)           3         361 (4.0)         0 (0.0)           4         59 (1.0)         0 (0.0)           5         20 (0.2)         0 (0.0)           5         20 (0.2)         0 (0.0)	insertion		
before insertion           Room intended for CVC insertion           Operating theatre $5336$ (54) $3$ (15)           Intensive Care Unit $2604$ (26) $12$ (60)           Room reserved for CVC $1321$ (13) $2$ (10)           insertion $286$ (3.0) $2$ (10)           Department of admission at CVC insertion $286$ (3.0) $2$ (10)           Department of admission at CVC insertion $3$ (15)           Medical ward $2905$ (29) $5$ (25)           Intensive Care Unit $1615$ (16) $9$ (45)           High risk patients $2159$ (22) $10$ (50)           Number of skin punctures $1$ $7450$ (75) $18$ (90)           2 $1545$ (16) $1$ (5.0) $3$ 3 $516$ (5.0) $0$ (0.0)           4 $122$ (1.0) $0$ (0.0)           5 or more $60$ (1.0) $0$ (0.0)           2 $1369$ (14) $1$ (5.0)           3 $361$ (4.0) $0$ (0.0)           4 $59$ (1.0) $0$ (0.0)           5 $20$ (0.2) $0$ (0.0) </td <td>Procoagulant treatment</td> <td>8577 (87)</td> <td>17 (85)</td>	Procoagulant treatment	8577 (87)	17 (85)
Room intended for CVC insertion           Operating theatre $5336$ (54) $3$ (15)           Intensive Care Unit $2604$ (26) $12$ (60)           Room reserved for CVC $1321$ (13) $2$ (10)           insertion         286 (3.0) $2$ (10)           Department of admission at CVC insertion         Surgical ward $5042$ (51) $3$ (15)           Medical ward         2905 (29) $5$ (25)           Intensive Care Unit $1615$ (16) $9$ (45)           High risk patients $2159$ (22) $10$ (50)           Number of skin punctures         1 $7450$ (75) $18$ (90)           2 $1545$ (16) $1$ (5.0) $3$ 3         516 (5.0) $0$ (0.0)           4 $122$ (1.0) $0$ (0.0)           5 or more $60$ (1.0) $0$ (0.0)           2 $1369$ (14) $1$ (5.0)           3 $361$ (4.0) $0$ (0.0)           4 $59$ (1.0) $0$ (0.0)           5 $20$ (0.2) $0$ (0.0)           5 $20$ (0.2) $0$ (0.0)	before insertion		
Operating theatre         5336 (54)         3 (15)           Intensive Care Unit         2604 (26)         12 (60)           Room reserved for CVC         1321 (13)         2 (10)           insertion         286 (3.0)         2 (10)           Department of admission at CVC insertion         3 (15)           Surgical ward         5042 (51)         3 (15)           Medical ward         2905 (29)         5 (25)           Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)           Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3           3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)           5 or more         60 (1.0)         0 (0.0)           2         1369 (14)         1 (5.0)           3         361 (4.0)         0 (0.0)           4         59 (1.0)         0 (0.0)           5         20 (0.2)         0 (0.0)           5         20 (0.2)         0 (0.0)	Room intended for CVC insertion		
Intensive Care Unit         2604 (26)         12 (60)           Room reserved for CVC         1321 (13)         2 (10)           insertion         286 (3.0)         2 (10)           Department of admission at CVC insertion         Surgical ward         5042 (51)         3 (15)           Medical ward         2905 (29)         5 (25)         Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)         Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)         4         122 (1.0)         0 (0.0)           5 or more         60 (1.0)         0 (0.0)         1369 (14)         1 (5.0)         3           3         361 (4.0)         0 (0.0)         4         59 (1.0)         0 (0.0)           4         59 (1.0)         0 (0.0)         5         20 (0.2)         0 (0.0)           5         20 (0.2)         0 (0.0)         5         20 (0.2)         0 (0.0)	Operating theatre	5336 (54)	3 (15)
Room reserved for CVC         1321 (13)         2 (10)           insertion         286 (3.0)         2 (10)           Department of admission at CVC insertion         Surgical ward         5042 (51)         3 (15)           Medical ward         2905 (29)         5 (25)         Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)         Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)         4         122 (1.0)         0 (0.0)           5 or more         60 (1.0)         0 (0.0)         1369 (14)         1 (5.0)           3         361 (4.0)         0 (0.0)         4         59 (1.0)         0 (0.0)           4         59 (1.0)         0 (0.0)         5         20 (0.2)         0 (0.0)           5         20 (0.2)         0 (0.0)         5         20 (0.2)         0 (0.0)	Intensive Care Unit	2604 (26)	12 (60)
Patient ward       286 (3.0)       2 (10)         Department of admission at CVC insertion	Room reserved for CVC insertion	1321 (13)	2 (10)
Department of admission at CVC insertion           Surgical ward         5042 (51)         3 (15)           Medical ward         2905 (29)         5 (25)           Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)           Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)         5 or more         60 (1.0)         0 (0.0)           5 or more         60 (1.0)         0 (0.0)         1650 (79)         18 (90)           2         1369 (14)         1 (5.0)         3         361 (4.0)         0 (0.0)           4         59 (1.0)         0 (0.0)         5         20 (0.2)         0 (0.0)           5         20 (0.2)         0 (0.0)         5         20 (0.2)         0 (0.0)	Patient ward	286 (3.0)	2 (10)
Surgical ward $5042$ (51) $3$ (15)Medical ward2905 (29) $5$ (25)Intensive Care Unit1615 (16) $9$ (45)High risk patients2159 (22)10 (50)Number of skin punctures $1$ 7450 (75)18 (90)21545 (16)1 (5.0)3516 (5.0)0 (0.0)4122 (1.0)0 (0.0)5 or more60 (1.0)0 (0.0)Number of punctured blood vessels $1$ 17850 (79)18 (90)21369 (14)1 (5.0)3361 (4.0)0 (0.0)459 (1.0)0 (0.0)520 (0.2)0 (0.0)Immediate mechanical complications $0$ No9432 (95)20 (100)Bleeding/punctured artery238 (2.0)0 (0.0)	Department of admission at CVC	insertion	
Medical ward         2905 (29)         5 (25)           Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)           Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)         5 or more         60 (1.0)         0 (0.0)           Number of punctured blood vessels         1         7850 (79)         18 (90)           2         1369 (14)         1 (5.0)         3         361 (4.0)         0 (0.0)           4         59 (1.0)         0 (0.0)         5         20 (0.2)         0 (0.0)           5         20 (0.2)         0 (0.0)         5         20 (0.2)         0 (0.0)	Surgical ward	5042 (51)	3 (15)
Intensive Care Unit         1615 (16)         9 (45)           High risk patients         2159 (22)         10 (50)           Number of skin punctures         1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)         3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)         5 or more         60 (1.0)         0 (0.0)           Number of punctured blood vessels         1         7850 (79)         18 (90)           2         1369 (14)         1 (5.0)         3         361 (4.0)         0 (0.0)           4         59 (1.0)         0 (0.0)         5         20 (0.2)         0 (0.0)           5         20 (0.2)         0 (0.0)         5         20 (0.2)         0 (0.0)	Medical ward	2905 (29)	5 (25)
High risk patients $2159 (22)$ $10 (50)$ Number of skin punctures $1$ $7450 (75)$ $18 (90)$ 2 $1545 (16)$ $1 (5.0)$ 3 $516 (5.0)$ $0 (0.0)$ 4 $122 (1.0)$ $0 (0.0)$ 5 or more $60 (1.0)$ $0 (0.0)$ Number of punctured blood vessels1 $7850 (79)$ $18 (90)$ 2 $1369 (14)$ $1 (5.0)$ 3 $361 (4.0)$ $0 (0.0)$ 4 $59 (1.0)$ $0 (0.0)$ 5 $20 (0.2)$ $0 (0.0)$ Immediate mechanical complicationsNo $9432 (95)$ $20 (100)$ Bleeding/punctured artery $238 (2.0)$ $0 (0.0)$	Intensive Care Unit	1615 (16)	9 (45)
Number of skin punctures           1         7450 (75)         18 (90)           2         1545 (16)         1 (5.0)           3         516 (5.0)         0 (0.0)           4         122 (1.0)         0 (0.0)           5 or more         60 (1.0)         0 (0.0)           Number of punctured blood vessels         1         7850 (79)         18 (90)           2         1369 (14)         1 (5.0)         3         361 (4.0)         0 (0.0)           4         59 (1.0)         0 (0.0)         5         20 (0.2)         0 (0.0)           5         20 (0.2)         0 (0.0)         5         20 (100)         1           Bleeding/punctured artery         238 (2.0)         0 (0.0)         0         0	High risk patients	2159 (22)	10 (50)
17450 (75)18 (90)21545 (16)1 (5.0)3516 (5.0)0 (0.0)4122 (1.0)0 (0.0)5 or more60 (1.0)0 (0.0)Number of punctured blood vessels17850 (79)18 (90)21369 (14)1 (5.0)3361 (4.0)0 (0.0)459 (1.0)0 (0.0)520 (0.2)0 (0.0)Immediate mechanical complicationsNo9432 (95)20 (100)Bleeding/punctured artery238 (2.0)0 (0.0)	Number of skin punctures		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1	7450 (75)	18 (90)
3       516 (5.0)       0 (0.0)         4       122 (1.0)       0 (0.0)         5 or more       60 (1.0)       0 (0.0)         Number of punctured blood vessels         1       7850 (79)       18 (90)         2       1369 (14)       1 (5.0)         3       361 (4.0)       0 (0.0)         4       59 (1.0)       0 (0.0)         5       20 (0.2)       0 (0.0)         Immediate mechanical complications         No       9432 (95)       20 (100)         Bleeding/punctured artery       238 (2.0)       0 (0.0)	2	1545 (16)	1 (5.0)
4122 (1.0)0 (0.0)5 or more $60 (1.0)$ $0 (0.0)$ Number of punctured blood vessels1 $7850 (79)$ $18 (90)$ 2 $1369 (14)$ $1 (5.0)$ 3 $361 (4.0)$ $0 (0.0)$ 4 $59 (1.0)$ $0 (0.0)$ 5 $20 (0.2)$ $0 (0.0)$ Immediate mechanical complicationsNo $9432 (95)$ $20 (100)$ Bleeding/punctured artery $238 (2.0)$ $0 (0.0)$	3	516 (5.0)	0 (0.0)
5 or more         60 (1.0)         0 (0.0)           Number of punctured blood vessels         1         7850 (79)         18 (90)           2         1369 (14)         1 (5.0)         3         361 (4.0)         0 (0.0)           3         361 (4.0)         0 (0.0)         5         20 (0.2)         0 (0.0)           Immediate mechanical complications         No         9432 (95)         20 (100)           Bleeding/punctured artery         238 (2.0)         0 (0.0)	4	122 (1.0)	0 (0.0)
Number of punctured blood vessels           1         7850 (79)         18 (90)           2         1369 (14)         1 (5.0)           3         361 (4.0)         0 (0.0)           4         59 (1.0)         0 (0.0)           5         20 (0.2)         0 (0.0)           Immediate mechanical complications         No         9432 (95)         20 (100)           Bleeding/punctured artery         238 (2.0)         0 (0.0)	5 or more	60 (1.0)	0 (0.0)
1       7850 (79)       18 (90)         2       1369 (14)       1 (5.0)         3       361 (4.0)       0 (0.0)         4       59 (1.0)       0 (0.0)         5       20 (0.2)       0 (0.0)         Immediate mechanical complications         No       9432 (95)       20 (100)         Bleeding/punctured artery       238 (2.0)       0 (0.0)	Number of punctured blood vesse	els	
$\begin{array}{cccccccc} 2 & 1369 & (14) & 1 & (5.0) \\ 3 & 361 & (4.0) & 0 & (0.0) \\ 4 & 59 & (1.0) & 0 & (0.0) \\ 5 & 20 & (0.2) & 0 & (0.0) \\ \hline \mmediate mechanical complications \\ \hline \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	1	7850 (79)	18 (90)
$\begin{array}{ccccccc} 3 & 361 & (4.0) & 0 & (0.0) \\ 4 & 59 & (1.0) & 0 & (0.0) \\ 5 & 20 & (0.2) & 0 & (0.0) \\ \hline \mbox{Immediate mechanical complications} \\ No & 9432 & (95) & 20 & (100) \\ \hline \mbox{Bleeding/punctured artery} & 238 & (2.0) & 0 & (0.0) \\ \hline \end{array}$	2	1369 (14)	1 (5.0)
4       59 (1.0)       0 (0.0)         5       20 (0.2)       0 (0.0)         Immediate mechanical complications         No       9432 (95)       20 (100)         Bleeding/punctured artery       238 (2.0)       0 (0.0)	3	361 (4.0)	0 (0.0)
5         20 (0.2)         0 (0.0)           Immediate mechanical complications         0	4	59 (1.0)	0 (0.0)
Immediate mechanical complicationsNo9432 (95)Bleeding/punctured artery238 (2.0)0 (0.0)	5	20 (0.2)	0 (0.0)
No 9432 (95) 20 (100) Bleeding/punctured artery 238 (2.0) 0 (0.0)	Immediate mechanical complicat	ions	. /
Bleeding/punctured artery $238(2.0)$ $0(0.0)$	No	9432 (95)	20 (100)
	Bleeding/punctured artery	238 (2.0)	0 (0.0)
Other 234 (2.0) 0 (0.0)	Other	234 (2.0)	0 (0.0)

<sup>a</sup> Numbers are presented with number (%) and continuous variables are presented with median [interquartile range]. Missing data is not presented in table.

variables affecting the outcome still cannot be ruled out. Further, the sample size was based on the number of available insertions during the study period meaning that the power of the results is uncertain. Last, the sensitivity of the automated script-base data extraction from the EHR has not been investigated in the current study. In summary, this large retrospective observational study demonstrated that automated data extraction of EHR data could be the base for quality assurance and epidemiological studies. Furthermore, the results indicate a sustained low incidence of CRI and CRBSI in the region and several associations between independent variables and both catheter tip colonisation and CRI, were identified. In addition, this study demonstrates that the choice of insertion site might impact the catheter tip colonisation rate. Male sex and an increased number of catheter lumens were associated with both catheter tip colonisation and CRI.

## Credit author statement

**Manuscript:** "Sustained low Catheter Relation Infection Incidence in Observational Follow-up Study of 9924 Catheters using Automatic Data Scripts as Quality Assurance for Central Venous Catheter Management" (IPIP-D-22-00062).

Mika M. Rockholt: Conceptualization, Methodology, Formal Analysis, Writing — Original Draft, Writing — Review & Editing, Visualization.

**Tobis Agrell:** Formal Analysis, Writing – Original Draft, Writing – Review & Editing.

Hulda Thorarinnsdottir: Writing – Review & Editing, Supervision.

**Thomas Kander:** Conceptualization, Methodology, Formal Analysis, Writing — Review & Editing, Supervision, Project Administration.

## **Conflict of interest**

Thomas Kander is on the Advisory Board of Bactiguard AB (Stockholm, Sweden) and of Anaesthesiology Intensive Therapy (Poland). The remaining authors have no conflicts of interest to declare.

## Funding

This research received funding from the following institutions: Scania Region Department of Quality Improvement (Sweden), Swedish Medical Association (Sweden), Lion's Research Fund (Sweden) and LÖF - The Swedish Patient Insurance (Sweden).

## Acknowledgements

The authors would like to thank Lena Hyllebusk, Biomedical Analyst, for her invaluable help with the data collection.

## References

- [1] Stevens V, Geiger K, Concannon C, Nelson RE, Brown J, Dumyati G. Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections. Clin Microbiol Infect 2014;20(5):O318–24. https://doi.org/10.1111/ 1469-0691.12407.
- [2] Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355(26):2725–32. https://doi.org/10.1056/NEJMoa061115.
- [3] Velasquez Reyes DC, Bloomer M, Morphet J. Prevention of central venous line associated bloodstream infections in adult intensive

care units: A systematic review. Intensive Crit Care Nurs 2017;43:12-22. https://doi.org/10.1016/j.iccn.2017.05.006.

- [4] Thorarinsdottir HR, Rockholt M, Klarin B, Broman M, Fraenkel CJ, Kander T. Catheter-related infections: a Scandinavian observational study on the impact of a simple hygiene insertion bundle. Acta Anaesthesiol Scand 2020;64(2):224–31. https://doi.org/ 10.1111/aas.13477.
- [5] Longmate AG, Ellis KS, Boyle L, Maher S, Cairns CJS, Lloyd SM, et al. Elimination of central-venous-catheter-related bloodstream infections from the intensive care unit. BMJ Qual Saf 2011;20(2):174. https://doi.org/10.1136/bmjqs.2009.037200.
- [6] Battistella M, Bhola C, Lok CE. Long-term follow-up of the hemodialysis infection prevention with polysporin ointment (HIPPO) Study: a quality improvement report. Am J Kidney Dis 2011;57(3):432-41. https://doi.org/10.1053/j.ajkd.2010.10.009.
- [7] Hammarskjöld F, Berg S, Hanberger H, Taxbro K, Malmvall B-E. Sustained low incidence of central venous catheter-related infections over six years in a Swedish hospital with an active central venous catheter team. Am J Infect Control 2014;42(2):122–8. https://doi.org/10.1016/j.ajic.2013.09.023.
- [8] Rinke ML, Heo M, Saiman L, Bundy DG, Rosenberg RE, DeLaMora P, et al. Pediatric ambulatory central Line—associated bloodstream infections. Pediatrics 2021;147(1). https://doi.org/10.1542/ peds.2020-0524.
- [9] Valik JK, Ward L, Tanushi H, Müllersdorf K, Ternhag A, Aufwerber E, et al. Validation of automated sepsis surveillance based on the Sepsis-3 clinical criteria against physician record review in a general hospital population: observational study using electronic health records data. BMJ Qual Saf 2020;29(9):735–45. https://doi.org/10.1136/bmjqs-2019-010123.
- [10] McNamara E, Adams D, Dellit TH. Improving central venous catheter insertion documentation to facilitate electronic surveillance of bundle compliance. Am J Infect Control 2011;39(9):779–81. https://doi.org/10.1016/j.ajic.2010.12.009.
- [11] Thate J, Rossetti SC, McDermott-Levy R, Moriarty H. Identifying best practices in electronic health record documentation to support interprofessional communication for the prevention of central line-associated bloodstream infections. Am J Infect Control 2020;48(2):124–31. https://doi.org/10.1016/j.ajic.2019. 07.027.
- [12] Björkander M, Bentzer P, Schött U, Broman ME, Kander T. Mechanical complications of central venous catheter insertions: A retrospective multicenter study of incidence and risks. Acta Anaesthesiol Scand 2019;63(1):61–8. https://doi.org/10.1111/ aas.13214.
- [13] Monsen T, Lovgren E, Widerstrom M, Wallinder L. In vitro effect of ultrasound on bacteria and suggested protocol for sonication and diagnosis of prosthetic infections. J Clin Microbiol 2009;47(8):2496–501. https://doi.org/10.1128/JCM.02316-08.
- [14] Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49(1):1-45. https://doi.org/10.1086/599376.

- [15] Garner J, Jarvis W, Emori T, Horan T, Hughes J. CDC definitions for nosocomial infections 1988. Am J Infect Control 1988;16(3):128–40. https://doi.org/10.1016/0196-6553(88) 90053-3.
- [16] Gowardman JR, Robertson IK, Parkes S, Rickard CM. Influence of insertion site on central venous catheter colonization and bloodstream infection rates. Intensive Care Med 2008;34(6):1038–45. https://doi.org/10.1007/s00134-008-1046-3.
- [17] Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev 2014;27(4):870–926. https:// doi.org/10.1128/CMR.00109-13.
- [18] Hammarskjöld F, Wallén G, Malmvall BE. Central venous catheter infections at a county hospital in Sweden: a prospective analysis of colonization, incidence of infection and risk factors. Acta Anaesthesiol Scand 2006;50(4):451–60. https://doi.org/10.1111/ j.1399-6576.2006.00974.x.
- [19] Liang X, Liu Y, Chen B, Li P, Zhao P, Liu Z, et al. Central Venous Disease Increases the Risk of Microbial Colonization in Hemodialysis Catheters. Front Med 2021;8. https://doi.org/10.3389/ fmed.2021.645539.
- [20] Moro ML, Vigano EF, Lepri AC, Group CVC-RIS. Risk factor for central venous catheter-related infections in surgical and intensive care units. Infect Control Hosp Epidemiol 1994;15(4):253–64. https://doi.org/10.2307/30145577.
- [21] Luft D, Schmoor C, Wilson C, Widmer AF, Bertz H, Frei R, et al. Central venous catheter-associated bloodstream infection and colonisation of insertion site and catheter tip. What are the rates and risk factors in haematology patients? Ann Hematol 2010;89(12):1265–75. https://doi.org/10.1007/s00277-010-1005-2.
- [22] Templeton A, Schlegel M, Fleisch F, Rettenmund G, Schöbi B, Henz S, et al. Multilumen Central Venous Catheters Increase Risk for Catheter-Related Bloodstream. Infection 2008;36(4):322. https://doi.org/10.1007/s15010-008-7314-x.
- [23] Kallen AJ, Patel PR, O'Grady NP. Preventing catheter-related bloodstream infections outside the intensive care unit: expanding prevention to new settings. Clin Infect Dis 2010;51(3):335–41. https://doi.org/10.1086/653942.
- [24] Rockholt MM, Thorarinsdottir HR, Lazarevic V, Rundgren M, Kander T. Central Venous Catheter Related Complications in Hematological Patients: An Observational Study. Acta Anaesthesiol Scand 2021. https://doi.org/10.1111/aas.14020.
- [25] Exline MC, Ali NA, Zikri N, Mangino JE, Torrence K, Vermillion B, et al. Beyond the bundle-journey of a tertiary care medical intensive care unit to zerocentral line-associated bloodstream infections. Crit Care 2013;17(2):1–13. https://doi.org/10.1186/cc12551.
- [26] Gokhale KM, Chandan JS, Toulis K, Gkoutos G, Tino P, Nirantharakumar K. Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies. Eur J Epidemiol 2021;36(2):165–78. https://doi.org/ 10.1007/s10654-020-00677-6.
- [27] Alzu'bi AA, Watzlaf VJM, Sheridan P. Electronic Health Record (EHR) Abstraction. Perspect Health Inf Manag 2021;18:1-14 (Spring).